Abstract
Pediatric antiretroviral treatment programs have been rolled out in resource limited settings, providing lifesaving treatment to approximately 300,000 HIV-infected children. The standard first-line antiretroviral regimen is a nonnucleoside reverse transcriptase plus 2 nucleoside reverse transcriptase inhibitors (NRTIs). A meta-analysis showed that 70% of children achieved virologic suppression after 12 months of first line therapy. This article presents the challenges in diagnosis of treatment failure in resource limited settings and reviews the current guidelines for management of HIV-infected children with second-line antiretroviral therapy. The details of antiretroviral drugs recommended for second line regimens are summarized. The current standard second-line regimen is a boostedprotease inhibitor-based regimen plus recycling NRTIs. The potential role of new ARV drug classes for second-line regimen is addressed.
Keywords: Pediatric HIV, antiretroviral therapy, resource limited settings
Current Pediatric Reviews
Title: Second-Line Antiretroviral Therapy for HIV-Infected Children in Resource Limited Settings
Volume: 7 Issue: 3
Author(s): Linda Aurpibul and Thanyawee Puthanakit
Affiliation:
Keywords: Pediatric HIV, antiretroviral therapy, resource limited settings
Abstract: Pediatric antiretroviral treatment programs have been rolled out in resource limited settings, providing lifesaving treatment to approximately 300,000 HIV-infected children. The standard first-line antiretroviral regimen is a nonnucleoside reverse transcriptase plus 2 nucleoside reverse transcriptase inhibitors (NRTIs). A meta-analysis showed that 70% of children achieved virologic suppression after 12 months of first line therapy. This article presents the challenges in diagnosis of treatment failure in resource limited settings and reviews the current guidelines for management of HIV-infected children with second-line antiretroviral therapy. The details of antiretroviral drugs recommended for second line regimens are summarized. The current standard second-line regimen is a boostedprotease inhibitor-based regimen plus recycling NRTIs. The potential role of new ARV drug classes for second-line regimen is addressed.
Export Options
About this article
Cite this article as:
Aurpibul Linda and Puthanakit Thanyawee, Second-Line Antiretroviral Therapy for HIV-Infected Children in Resource Limited Settings, Current Pediatric Reviews 2011; 7 (3) . https://dx.doi.org/10.2174/157339611796548375
DOI https://dx.doi.org/10.2174/157339611796548375 |
Print ISSN 1573-3963 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6336 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Toxicity by NSAIDs. Counteraction by Stable Gastric Pentadecapeptide BPC 157
Current Pharmaceutical Design Patent Selections
Recent Patents on Inflammation & Allergy Drug Discovery Fulvestrant - A Novel Endocrine Therapy for Breast Cancer
Current Medicinal Chemistry Possible Involvement of Angiogenesis in Chronic Liver Diseases: Interaction Among Renin-Angiotensin-Aldosterone System, Insulin Resistance and Oxidative Stress
Current Medicinal Chemistry Novel Treatment Options of Binge Eating Disorder
Current Medicinal Chemistry Release of Adenosine and ATP During Ischemia and Epilepsy
Current Neuropharmacology Analytical and Pharmacological Aspects of Therapeutic Drug Monitoring of mTOR Inhibitors
Current Drug Metabolism Trace Elements Supplementation: Recent Advances and Perspectives
Mini-Reviews in Medicinal Chemistry Implications of Angiotensin II in Central Nervous System on Exercise Performance
Current Protein & Peptide Science Current HIV Treatment Guidelines - An Overview
Current Pharmaceutical Design The Association between Serum Asymmetric Dimethylarginine and Coronary Atherosclerotic Plaque in an Asymptomatic Population
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Editorial [Hot topic: Controversies in Hypertension Treatment (Guest Editors: Maciej Banach, Sverre E. Kjeldsen and Krzysztof Narkiewicz)]
Current Vascular Pharmacology mGluRI Targets Microglial Activation and Selectively Prevents Neuronal Cell Engulfment Through Akt and Caspase Dependent Pathways
Current Neurovascular Research The Association between HbA1c Levels, Olfactory Memory and Cognition in Normal, Pre-Diabetic and Diabetic Persons
Endocrine, Metabolic & Immune Disorders - Drug Targets Triptolide Improves Renal Injury in Diabetic Nephropathy Rats through TGF-β1/Smads Signal Pathway
Endocrine, Metabolic & Immune Disorders - Drug Targets Targeting Transient Receptor Potential Canonical Channels for Diseases of the Nervous System
Current Drug Targets Anti-cancer Peptides from Ras-P21 and P53 Proteins
Current Pharmaceutical Design Editorial: Can Glucagon Like Peptide 1 (GLP1) Agonists or Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors Ameliorate Non-Alcoholic Steatohepatitis in People with or without Diabetes?
Current Vascular Pharmacology Solvent-Free and Self-Catalyzed Three-Component Synthesis of Diversely Substituted Pyrazolo[1,4]thiazepinones of Potential Antitumor Activity
Current Organic Synthesis Genome Study of Kidney Disease in the Age of Post Genome-Sequencing
Endocrine, Metabolic & Immune Disorders - Drug Targets